{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:03:59Z","timestamp":1768885439462,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["57862"],"award-info":[{"award-number":["57862"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12288-022-01532-2","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T07:04:02Z","timestamp":1649660642000},"page":"668-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7450-2957","authenticated-orcid":false,"given":"Betul","family":"Bozkurt Bulakc\u0131","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-0646","authenticated-orcid":false,"given":"Aynur","family":"Daglar Aday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8806-2270","authenticated-orcid":false,"given":"Basak","family":"Gurtekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9049-4654","authenticated-orcid":false,"given":"Akif Selim","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-7462","authenticated-orcid":false,"given":"Sukru","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9420-4543","authenticated-orcid":false,"given":"Kivanc","family":"Cefle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9376-4039","authenticated-orcid":false,"given":"Ayse","family":"Palanduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9435-009X","authenticated-orcid":false,"given":"Sukru","family":"Palanduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"1532_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","author":"A de Klein","year":"1982","unstructured":"de Klein A, van Kessel AG, Grosveld G et al (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300:765\u2013767","journal-title":"Nature"},{"key":"1532_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P et al (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938\u20131942","journal-title":"Science"},{"key":"1532_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561\u2013566","journal-title":"Nat Med"},{"key":"1532_CR4","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E et al (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437\u20134444","journal-title":"Blood"},{"key":"1532_CR5","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8:1018\u20131029","journal-title":"Lancet Oncol"},{"key":"1532_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.003","volume":"274","author":"G Volpe","year":"2009","unstructured":"Volpe G, Panuzzo C, Ulisciani S et al (2009) Imatinib resistance in CML. Cancer Lett 274:1\u20139","journal-title":"Cancer Lett"},{"key":"1532_CR7","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","volume":"15","author":"D Milojkovic","year":"2009","unstructured":"Milojkovic D, Apperley J (2009) Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 15:7519\u20137527","journal-title":"Clin Cancer Res"},{"key":"1532_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.leukres.2014.12.008","volume":"39","author":"R Alves","year":"2015","unstructured":"Alves R, Fonseca AR, Gon\u00e7alves AC et al (2015) Drug transporters play a key role in the complex process of Imatinib resistance in vitro. Leuk Res 39:355\u2013360","journal-title":"Leuk Res"},{"key":"1532_CR9","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","volume":"14","author":"S Hu","year":"2008","unstructured":"Hu S, Franke RM, Filipski KK et al (2008) Interaction of imatinib with human organic ion carriers. Clin Cancer Res 14:3141\u20133148","journal-title":"Clin Cancer Res"},{"key":"1532_CR10","first-page":"2043","volume":"18","author":"S Chhikara","year":"2017","unstructured":"Chhikara S, Sazawal S, Seth T et al (2017) Molecular response to \u0131matinib and \u0131ts correlation with mrna expression levels of \u0131matinib \u0131nflux transporter (OCT1) in Indian chronic myeloid leukemia patients. Asian Pac J Cancer Prev 18:2043\u20132048","journal-title":"Asian Pac J Cancer Prev"},{"key":"1532_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","volume":"17","author":"K Eechoute","year":"2011","unstructured":"Eechoute K, Sparreboom A, Burger H et al (2011) Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 17:406\u2013415","journal-title":"Clin Cancer Res"},{"key":"1532_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697\u2013704","journal-title":"Blood"},{"key":"1532_CR13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00280-015-2905-6","volume":"76","author":"J Francis","year":"2015","unstructured":"Francis J, Dubashi B, Sundaram R et al (2015) A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients. Cancer Chemother Pharmacol 76:1185\u20131189","journal-title":"Cancer Chemother Pharmacol"},{"key":"1532_CR14","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.3109\/10428194.2011.584005","volume":"52","author":"M Gromicho","year":"2011","unstructured":"Gromicho M, Dinis J, Magalh\u00e3es M et al (2011) Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma 52:1980\u20131990","journal-title":"Leuk Lymphoma"},{"key":"1532_CR15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/1078-0432.CCR-13-1999","volume":"20","author":"AT Nies","year":"2014","unstructured":"Nies AT, Schaeffeler E, van der Kuip H et al (2014) Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res 20:985\u2013994","journal-title":"Clin Cancer Res"},{"key":"1532_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00280-017-3266-0","volume":"79","author":"I Ben Hassine","year":"2017","unstructured":"Ben Hassine I, Gharbi H, Soltani I et al (2017) hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 79:737\u2013745","journal-title":"Cancer Chemother Pharmacol"},{"key":"1532_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/0971-5916.164250","volume":"142","author":"H Malhotra","year":"2015","unstructured":"Malhotra H, Sharma P, Malhotra B et al (2015) Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase. Indian J Med Res 142:175\u2013182","journal-title":"Indian J Med Res"},{"key":"1532_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.clml.2018.02.004","volume":"18","author":"S Rinaldetti","year":"2018","unstructured":"Rinaldetti S, Pfirrmann M, Manz K et al (2018) Effect of ABCG2, OCT1, and ABCB1 (MDR1) gene expression on treatment-free remission in a EURO-SKI subtrial. Clin Lymphoma Myeloma Leuk 18:266\u2013271","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1532_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3324\/haematol.2010.033290","volume":"96","author":"JR Engler","year":"2011","unstructured":"Engler JR, Zannettino AC, Bailey CG et al (2011) OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica 96:213\u2013220","journal-title":"Haematologica"},{"key":"1532_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","volume":"115","author":"SK McWeeney","year":"2010","unstructured":"McWeeney SK, Pemberton LC, Loriaux MM et al (2010) A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 115:315\u2013325","journal-title":"Blood"},{"issue":"6","key":"1532_CR21","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"key":"1532_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method. Methods 25:402\u2013408","journal-title":"Methods"},{"key":"1532_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.canlet.2011.08.009","volume":"312","author":"R Tanaka","year":"2011","unstructured":"Tanaka R, Kimura S, Ashihara E et al (2011) Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Lett 312:228\u2013234","journal-title":"Cancer Lett"},{"key":"1532_CR24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/leu.2010.86","volume":"24","author":"A Bazeos","year":"2010","unstructured":"Bazeos A, Marin D, Reid AG et al (2010) hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 24:1243\u20131245","journal-title":"Leukemia"},{"key":"1532_CR25","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s12032-014-0851-5","volume":"31","author":"LT de Lima","year":"2014","unstructured":"de Lima LT, Vivona D, Bueno CT et al (2014) Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Med Oncol 31:851","journal-title":"Med Oncol"},{"key":"1532_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000336610","volume":"127","author":"L Nardinelli","year":"2012","unstructured":"Nardinelli L, Sanabani SS, Didone A et al (2012) Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia. Acta Haematol 127:228\u2013234","journal-title":"Acta Haematol"},{"key":"1532_CR27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3892\/or.2012.2153","volume":"29","author":"M Gromicho","year":"2013","unstructured":"Gromicho M, Magalh\u00e3es M, Torres F et al (2013) Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Oncol Rep 29:741\u2013750","journal-title":"Oncol Rep"},{"issue":"10","key":"1532_CR28","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1038\/s41375-018-0101-5","volume":"32","author":"LN Eadie","year":"2018","unstructured":"Eadie LN, Hughes TP, White DL (2018) Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy. Leukemia 32(10):2288\u20132291","journal-title":"Leukemia"},{"key":"1532_CR29","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","volume":"106","author":"LC Crossman","year":"2005","unstructured":"Crossman LC, Druker BJ, Deininger MW et al (2005) hOCT 1 and resistance to Imatinib. Blood 106:1133\u20131134","journal-title":"Blood"},{"key":"1532_CR30","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064\u20134072","journal-title":"Blood"},{"key":"1532_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","volume":"83","author":"L Wang","year":"2008","unstructured":"Wang L, Giannoudis A, Lane S et al (2008) Expression of the uptake drug transporter hoct1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83:258\u2013264","journal-title":"Clin Pharmacol Ther"},{"key":"1532_CR32","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","volume":"28","author":"DL White","year":"2010","unstructured":"White DL, Dang P, Engler J et al (2010) Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 28:2761\u20132767","journal-title":"J Clin Oncol"},{"key":"1532_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000336244","volume":"127","author":"JS Zhong","year":"2012","unstructured":"Zhong JS, Meng FY, Xu D et al (2012) Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients. Acta Haematol 127:221\u2013227","journal-title":"Acta Haematol"},{"key":"1532_CR34","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12185-011-0924-6","volume":"94","author":"F Razga","year":"2011","unstructured":"Razga F, Racil Z, Polakova KM et al (2011) The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia. Int J Hematol 94:303\u2013306","journal-title":"Int J Hematol"},{"key":"1532_CR35","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","volume":"27","author":"WW Zhang","year":"2009","unstructured":"Zhang WW, Cortes JE, Yao H et al (2009) Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 27:3642\u20133649","journal-title":"J Clin Oncol"},{"key":"1532_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/bjh.12591","volume":"163","author":"J Grinfeld","year":"2013","unstructured":"Grinfeld J, Gerrard G, Alikian M et al (2013) A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. Br J Haematol 163:631\u2013639","journal-title":"Br J Haematol"},{"key":"1532_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1309\/LMP1ECAE30JSVZEP","volume":"44","author":"S Solali","year":"2013","unstructured":"Solali S, Kaviani S, Movassaghpour AA et al (2013) Real-time polymerase chain reaction testing for quantitative evaluation of hOCT1 and MDR1 expression in patients with chronic myeloid leukemia resistant to imatinib. Lab Med 44:13\u201319","journal-title":"Lab Med"},{"key":"1532_CR38","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1182\/blood.V122.21.4041.4041","volume":"122","author":"CC Mascarenhas","year":"2013","unstructured":"Mascarenhas CC, Almeida MH, Miranda EC et al (2013) Evaluation of hOCT1 expression in patients with chronic myeloid leukemia (CML) treated with imatinib in first line. Blood 122:4041","journal-title":"Blood"},{"key":"1532_CR39","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","volume":"121","author":"A Giannoudis","year":"2013","unstructured":"Giannoudis A, Wang L, Jorgensen AL et al (2013) The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420delmodifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 121:628\u2013637","journal-title":"Blood"},{"key":"1532_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.12659\/MSMBR.909124","volume":"24","author":"S Sreenivasan Tantuan","year":"2018","unstructured":"Sreenivasan Tantuan S, Viljoen CD (2018) Imatinib affects the expression of SLC22A1 in a non-linear concentration-dependent manner within 24 hours. Med Sci Monit Basic Res 24:59\u201362","journal-title":"Med Sci Monit Basic Res"},{"key":"1532_CR41","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C et al (2007) Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21:926\u2013935","journal-title":"Leukemia"},{"key":"1532_CR42","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4068\/cmj.2014.50.3.102","volume":"50","author":"YK Kim","year":"2014","unstructured":"Kim YK, Lee SS, Jeong SH et al (2014) OCT-1, ABCB1, and ABCG2 expression in imatinib-resistant chronic myeloid leukemia treated with dasatinib or nilotinib. Chonnam Med J 50:102\u2013111","journal-title":"Chonnam Med J"},{"key":"1532_CR43","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","volume":"95","author":"E Weisberg","year":"2000","unstructured":"Weisberg E, Griffin JD (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines. Blood 95:3498\u20133505","journal-title":"Blood"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-022-01532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-022-01532-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-022-01532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T09:18:08Z","timestamp":1665825488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-022-01532-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1532"],"URL":"https:\/\/doi.org\/10.1007\/s12288-022-01532-2","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"30 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study was conducted in accordance with the ethical principles stated in the \u201cDeclaration of Helsinki\u201d. The study was approved by the Clinical Research Ethics Committee of the Istanbul Medical Faculty, Istanbul University (Decision number\/date: 1330\/June 26, 2015).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Eth\u0131cal Approval"}},{"value":"Written informed consent was obtained from each subject following a detailed explanation of the objectives and protocol of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}